Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AN2 Therapeutics, Inc.ANTX · Entity 1085 | Chief Medical Officer | March 15, 2024 | March 29, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AN2 Therapeutics, Inc.
Report date March 15, 2024 · Filed March 29, 2024 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 51,416 |
Reported balance
After 2024-03-15 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2024-03-15 · Grant · Acquired 30,000 · Balance 51,416 F1: Previously reported on a Form 4 filed on March 18, 2024. As amended, the vesting schedule for the restricted stock units is as follows: 1/4th of the shares vests annually over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Previously reported on a Form 4 filed on March 18, 2024. As amended, the vesting schedule for the restricted stock units is as follows: 1/4th of the shares vests annually over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 15, 2024 Filed Mar 18, 2024 23:27 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000165 · form4.xml · derivative · entry 2 Eckburg Paul · CIK 0001914512 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2034-03-14 F3 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date. Read SEC document |
| March 15, 2024 Filed Mar 18, 2024 23:27 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantCommon | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000165 · form4.xml · nonDerivative · entry 1 Eckburg Paul · CIK 0001914512 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,416 F1 · shares: These restricted stock units vest as follows: 1/16th of the shares vests quarterly over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date. F2 · balance_after: Reflects the adjusted total which includes the purchase of 3,127 shares under the AN2 Therapeutics, Inc. 2022 Employee Stock Purchase Plan on March 31, 2023. Read SEC document |
| March 15, 2024 Filed Mar 29, 2024 20:19 UTC Amendment | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000196 · form4.xml · nonDerivative · entry 1 Eckburg Paul · CIK 0001914512 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,416 F1 · shares: Previously reported on a Form 4 filed on March 18, 2024. As amended, the vesting schedule for the restricted stock units is as follows: 1/4th of the shares vests annually over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date. Read SEC document |
| February 15, 2023 Filed Feb 18, 2023 00:25 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 70,950 | $0.00 Strike: $14.29 | $0.00 |
DisclosureSEC source: 0000899243-23-005555 · doc4.xml · derivative · entry 1 Eckburg Paul · CIK 0001914512 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,950 Underlying: Common Stock · 70,950 shares Expires 2033-02-14 F1 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary as measured from January 1, 2023. Read SEC document |
| May 12, 2022 Filed May 17, 2022 01:23 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 66,000 | $0.00 Strike: $17.28 | $0.00 |
DisclosureSEC source: 0000899243-22-018292 · doc4.xml · derivative · entry 1 Eckburg Paul · CIK 0001914512 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,000 Underlying: Common Stock · 66,000 shares Expires 2032-05-11 F1 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary as measured from March 25, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.